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Introduction
In recent decades, major outbreaks of emerging 
infectious diseases have become a serious and recurrent 
problem. According to a study published in Nature, 
about 40 new pathogens have been identified since 
the beginning of the new millennium, many of them 
from animal reservoirs  [1]. In fact, most of these new 
infections are zoonoses, since they may originate in 
animals, at least in their initial emergence. Among all 
microorganisms, the ones that best fulfill the role of an 
emerging pathogen are viruses. In general, the risk of 
contracting a new virus of animal origin depends on the 
frequency of contact between humans and the animal 
species that is infected (the natural host). Measles and 
smallpox probably passed from livestock to humans with 
the introduction of farming over 10,000 years ago. In 
recent years, new viruses have emerged with increasing 
frequency from the animal context and have become a 
major global health threat: avian flu, Hendra, Nipah, 
SARS-CoV, MERS-CoV, Ebola, Zika, Chikungunya are 
just a few examples [2, 3].
The frequent emergence of zoonoses and their penetration 
into humans depend on many factors. Economic interests 
are leading to deforestation and therefore destruction of 
natural habitats with, as a consequence, greater contact 
among wild animals, domestic animals and humans. 
The trade of bushmeat in urban markets, once limited to 
rural areas, represents another factor that could carry new 
pathogens to humans. Climate change has also a significant 
role in facilitating the progressive movement of vectors 
towards previously un-infested areas. Furthermore, with 
the multiplicity of aspects of globalization and with 
the abolition of previous barriers, humans, animals and 
goods can move over long distances and reach different 
continents in a few hours. Hence, the conclusion that “a 
health threat anywhere is a health threat everywhere”. 
Coping with the spread of new infectious diseases 
therefore requires a worldwide coordinated effort, that is 
at the same time in the realm of a health response as well 
as of political and economic nature. 
The current international debate about COVID-19 
vaccines is today the hottest topic in global health 
whether it relates to technical and scientific issues or 
to the ethical aspects of access to vaccinations for all. 
Through an unprecedented research and development 
process, in early 2021, just one year after the COVID-19 
pandemic started devastating the world, there are several 
vaccines commercially available or in advances phase of 
testing, each with its own characteristics and challenges. 
This article aims at reviewing the status of vaccines that 
are used, or about to be used, in immunization campaigns 
worldwide.
An unprecedented research  
and implementation effort
The remarkable phenomenon one has witnessed in the 
past several months is that, after the approval of the 
first vaccines from Pfizer-BioNTech, Moderna and 
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AstraZeneca, other pharmaceutical companies have 
continued their research efforts, and stringent regulatory 
authorities have not shied away from the preparatory 
work to approve new vaccines. This is per se something 
exceptional, as is the recent announcement that two 
competitor pharmaceutical companies have agreed to 
cooperate in the production of a vaccine that one of the 
two has developed  [4]. In fact, it would be imprudent 
to rely on one vaccine only to cope with a major 
health emergency such as this pandemic that requires a 
simultaneous response worldwide. The need of billions 
of doses to be made readily available clashes with the 
pharmaceutical industry production capacity, and this 
has prompted an unprecedented intensive response 
by industry and governments. Indeed, one has little 
options: several vaccines must be developed, and all 
those authorized must be rapidly put into use through 
effective and strategic campaigns in every country. At the 
moment, clinical trials are being conducted worldwide 
on over 80 vaccines, half of which have reached the final 
phase of experimentation, and at least 180 experimental 
products are currently in preclinical phase of trials and 
animal testing has started [5]. Nine vaccines were already 
authorized in some countries for emergency use based 
on preliminary evidence of their safety and efficacy, and 
eight of them (Pfizer/BioNTech, Moderna, AstraZeneca, 
Cansino, Sinovac, Sinopharm Wuhan, Gamaleya, Vector 
Institute) were approved by regulatory agencies in some 
other countries after review of the final trial results [6].
The progress carried in the biotechnology field over 
the past few years has provided an important boost in 
the development of vaccines produced through the use 
of less complex and less expensive methods such as 
genetic engineering techniques. These techniques allow 
to obtain in a short time massive amounts of vaccines 
compared to traditional techniques which were based on 
the isolation followed by the attenuation or inactivation, 
and finally the purification of the pathogen. Regardless 
of the technology used in their development, all 
vaccines approved or still under study were developed 
to stimulate in the vaccinated individuals an immune 
response targeting the blockage of the SARS-CoV-2’s 
Spike protein which has a key role in the viral entry into 
human cells.
EMA and FDA approved vaccines
The European Medicines Agency (EMA) is the agency of 
the European Union (EU) responsible for the evaluation 
and supervision of  medicinal products. As of the end 
of May 2021, the EMA had approved four COVID-19 
vaccines: two of them are mRNA vaccines and two are 
viral vector vaccines. The other major stringent regulatory 
authority is the US Food and Drug Administration 
(FDA) that had approved, as of the end of May 2021, 
three vaccines: two are the same mRNA-based vaccines 
approved by EMA, while one is a viral vector vaccine. 
Table  I shows the main characteristics of the EMA and 
FDA approved vaccines as of the end of May 2021.
mRNA-based vaccines approved by both EMA 
and FDA 
Pfizer/BioNTech (BNT162) and Moderna (mRNA-1273) 
vaccines were approved by EMA in December 2020 and 
January 2021 respectively, and by FDA, which issued 
emergency use authorizations in December 2020 and 
extended them in May 2021 to include adolescents 
between 12 and 15 years of age [7].
They are both composed of molecules of messenger 
ribonucleic acid (mRNA) which contains the instructions 
for the synthesis of the Spike protein in the cells of the 
vaccinated subject. Both vaccines were demonstrated to be 
safe in clinical trials. They require two administrations (at 
21 or 28 days from the first administration, with a maximum 
delay between two doses of 42 days). The Pfizer/BioNTech 
vaccine phase 3 trial [8] involved 43,998 subjects between 
12 and 85 years of age who received both doses, whereas 
Moderna phase 3  trial  [9] included 30,000  participants 
older than 18  years (3,000  teenagers between 12 and 
Tab. I. Characteristics of the four COVID-19 vaccines approved by stringent regulatory authorities and available in Europe as of the end of 
March 2021.
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18 years were also included) receiving the two doses. The 
most common reported side effects related to BNT162 
were fatigue (3.8%), headache (2%), together with 
severe allergic reactions (2/10,000 vaccinated subjects in 
United Kingdom). Fatigue (9.7%), muscle and joint pain 
(8.9% and 5.2%), headache and injection site erythema 
were described for mRNA-1273 vaccine. The efficacy 
estimated in these trials was 95% (95% CI: 91-98%) for 
the Pfizer/BioNTech vaccine, with 170 infections reported 
at 4 weeks from the 2nd administration. For the Moderna 
vaccine the estimated efficacy was 94% (95%  CI: 
90-97%) with 196 infections reported at 2 weeks from the 
2nd administration. In addition, the Moderna mRNA-1273 
vaccine had an efficacy of 86% (95%  CI: 61-95%) 
among patients over 55 years old [10], compared to 95% 
(95% CI: 67-100%) of the Pfizer/BioNTech product. The 
major drawback of these two mRNA-based vaccines is 
the storage requirement at -70°C (or 2-8°C for 5 days) for 
the Pfizer/BioNTech vaccine and at -20°C (for 6 months) 
for the Moderna vaccine.
Because of their safety and high efficacy, these two 
mRNA-based vaccines are now recommended in persons 
older than 16 years, in particular in high-risk individuals 
that are more vulnerable to severe forms of COVID-19. 
At the end of May 2021, EMA and AIFA approved the 
use of the vaccine from Pfizer/BioNTech in adolescents 
from 12 to 15 years [11].
Viral vector vaccines approved by EMA and FDA
AstraZeneca/Vaxzevria’s vaccine, ChAdOx1 nCoV-19, 
is the viral vector-based vaccine approved by EMA and 
filed for FDA approval. It uses a modified version of a 
chimpanzee’s adenovirus which is not able to replicate 
but can provide the instructions for the Spike protein 
synthesis. Once the protein is produced, it can stimulate 
a specific immune response of both cellular and humoral 
nature. Compared to mRNA-based vaccines, this vaccine 
has a better stability which does not require excessively 
cold temperatures for storage and transportation 
(between -8 and +2°C). The phase 3 trial on the vaccine 
involved more than 24,000 subjects aged over 18 years 
from UK, Brazil and South Africa.
It requires 2  administrations. The efficacy in subjects 
who received two standard doses was 66.7% 
(95%  CI:  57.4-74.0%) and 81  infectious cases were 
described among vaccinated individuals 2  weeks after 
the 2nd administration. However, the efficacy was 76% 
after a single standard dose (from day 22 to day  90). 
Most participants in the UK received the booster dose 
more than 12  weeks from the first administration, 
and the vaccine efficacy was higher in this population 
(81.3%) compared with those who received the second 
administration earlier  [12]. The primary analysis of a 
trial conducted on over thirty thousand patients in the US 
showed an overall efficacy of 76% (95% CI: 68-82%) 
after the 2nd dose and an efficacy of 85% (95% CI: 58-
95%) in adults older than 65 [13].
Its safety and efficacy in older age groups was assessed 
on a phase 2/3  trial carried out in the UK involving 
240  adults older than 70  years. Local and systemic 
reactions were less frequent in older age groups, 
with similar humoral and cellular immune responses 
compared to younger populations  [14]. Earlier on, 
doubts on safety arose due to two cases of transverse 
myelitis being described following vaccination (at 10 
and 14  days from the 2nd  administration). Both cases 
were later reported to be unlikely related to the vaccine. 
However, later the use of the vaccine was associated 
with some deaths in different European countries that 
were attributed to thromboembolic events. These were 
mainly reported within 14  days from the first dose in 
individuals younger than 60  years and with a greater 
frequency in females. This phenomenon has been 
attributed to a response similar to the one occurring 
in heparin-induced thrombocytopenia. These adverse 
events prompted some EU countries (e.g.,  Austria, 
Bulgaria, Denmark, Estonia, Germany, Iceland, Italy 
Latvia, Lithuania, Luxembourg, Norway and Romania) 
to suspend the administration of the vaccine as a 
precautionary measure pending further investigations. 
The EMA’s safety committee (PRAC), after reviewing 
the available information, on 18 March 2021 suggested 
that “the vaccine’s benefits continue to outweigh the risks 
of side effects”, adding that the vaccine is not associated 
with an increased risk of thromboembolic events nor 
that specific batches were related to those events. WHO 
confirmed the recommendations of the EMA stating 
that the “benefits of the AstraZeneca vaccine outweigh 
its risks” and therefore recommended that vaccination 
campaigns continue  [15]. However, in April 2021, as 
further episodes of thromboembolic events (in particular 
cerebral sinus vein thrombosis: 169 identified cases; and 
splanchnic vein thrombosis: 53 cases) were described, the 
European PRAC committee advised that very rare cases 
of  thromboembolism associated to  thrombocytopenia 
should be included as possible side effects of Vaxzevria 
vaccine [16].
As of May 2021, EMA and WHO still recommend the 
administration of the vaccine with a careful monitoring 
of vaccinated individuals, and a preferential use in 
individuals older than 60  years has been adopted in 
different countries. 
The Johnson & Johnson vaccine, recently approved 
by the US FDA and by EMA  [17], is a viral vector-
based vaccine, which uses type 26  human adenovirus 
administered intramuscularly to adults  ≥  18  years of 
age. It requires a single administration and its storage 
temperature does not represent a problem as it can be 
kept stable for 3 months at +2/+8°C and for 2 years at 
-20°C. This vaccine was tested in over 43,000 subjects of 
different age groups (including 34% over age 60) and at 
different latitudes, from the USA to Latin America and 
South Africa. It was especially evaluated in patients with 
comorbidities such as obesity, diabetes, cancers, HIV, 
obtaining results reaching 100% efficacy in preventing 
hospitalization or death, and 85% against severe forms 
of COVID-19  [18]. Furthermore, this vaccine was 
tested in South Africa when the South African variant 
was already in circulation. The mean efficacy in 
moderate to severe forms was 65%, meaning that it has 
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partial efficacy against the variant. The most common 
adverse events reported in the trial were injection site 
reactions, headache, fatigue, myalgia, nausea and 
fever [19]. Similar to the case of Vaxzevria, some cases 
of thrombosis with thrombocytopenia were described in 
patients who received Janssen’s vaccine. For this reason, 
at the end of April 2021, EMA listed these events as a 
very rare side effect of the vaccine, still recommending, 
however, its usage [20].
Of relevance, Johnson and Johnson is planning to start 
testing in children between 2  months and 18  years in 
different international centers. Based on all these 
considerations, the US-based company filed phase 3 trial 
data for a single administration of its anti-COVID-19 
vaccine and the US FDA authorized it for use in 
emergency situations on February 27th, 2021. 
Remarkably, a very recent agreement between Johnson 
& Johnson and its competitor pharmaceutical giant 
Merck & Co, brokered by the White House, could 
lead to a faster production of the vaccine in the US. 
According to this agreement, Merck & Co will be co-
manufacturing the Johnson & Johnson vaccine thus 
allowing production of enough doses sufficient to cover 
the entire adult population of the United States by the 
end of May [4]. The EU authorized at the beginning of 
March the emergency use of the vaccine and already 
established an agreement for the purchase of 200 million 
doses together with an option for another 200 million 
doses. 
Vaccines being considered for approval
Sputnik V
The delays in the delivery by Pfizer and the safety 
concerns arisen by the AstraZeneca vaccine are now 
prompting the EMA to explore approval of the Russian 
Sputnik V vaccine which may result in purchasing by 
the EU Member States. The Sputnik V vaccine was so 
named from the first Soviet space satellite, Sputnik-1, 
which was launched in 1957. This event resulted in a 
new boost to space research all over the world creating 
the so-called “Sputnik moment” shared by the global 
community. This viral vector vaccine employs two 
human adenoviruses (rAd26 and rAd5) which transfer 
the SARS-CoV-2 Spike protein gene into human cells. 
Human adenoviruses are considered among the easiest 
viruses to engineer and therefore became very popular 
vectors. Sputnik V utilizes these two distinct adenovirus 
vectors dispensed separately in two administrations at 
21 days distance from one another and induces a strong 
and specific antibody response against SARS-CoV-2. 
This strategy is conceived to prevent development of 
immunity against the first adenovirus injected (rAd26) 
which could impair response to the booster dose if the 
same virus were used as vector. This vaccine has now 
been registered in more than 25 countries. The clinical 
study post Sputnik V registration carried out in Russia 
involved more than 31,000 volunteers (study population 
between 18 and 60 years) while phase 3 clinical trials were 
conducted in United Arab Emirates, India, Venezuela 
and Belarus. Initially, doubts arose regarding the efficacy 
of the vaccine lacking assessment by an independent 
stringent regulatory agency. These doubts however were 
successfully addressed by a large study finally published 
in February 2021 [21]. This study showed an efficacy of 
91.6% (95% CI: 85.6-95.2%) based on the analysis of 
data from almost 20.000 volunteers (18-87 years) who 
received both a first and second administration either of 
the vaccine or of a placebo. 
Starting at 21 days after the first dose of vaccine (the 
day of dose 2), 16 (0.1%) of 14,964 participants in the 
vaccine group and 62 (1.3%) of 4,902 in the placebo 
group developed COVID-19; vaccine efficacy was 
therefore estimated to be 91.6% (95%  CI:  85.6-95.2). 
Of note, the vaccine efficacy was 91.8% (95% CI: 67.1-
98.3) in participants older than 60 years. The study 
also showed the safety of Sputnik V, the most common 
adverse events being flu-like illness and local reactions, 
observed, respectively, in 156 and 56 participants in the 
vaccine group. The freeze-dried form of the vaccine can 
be stored at temperatures between +2 and +8°C, which 
is a strong point in favour of this product since it allows 
for an easier distribution around the world including 
in areas which are difficult to reach or when the cold 
chain cannot be guaranteed. In Moscow, Russia, the 
vaccine is administered in drugstores and even in some 
supermarkets. 
Novavax
The Novavax NVX-CoV2373 vaccine is a protein-based 
vaccine composed of SARS-CoV-2 Spike recombinant 
proteins. It contains an “adjuvant” (saponins), which 
contributes to strengthen the immune response to 
the vaccine. Two administrations are planned to be 
dispensed at 21  days distance from each other. The 
vaccine target is set to adults between 18 and 84 years 
of age. Novavax vaccine can be stored between 
2 and 8°C and is shipped in a ready-to-use liquid 
formulation. The company announced an efficacy of 
89.3% (95% CI: 75.2-95.4%) following a phase 3 trial 
conducted in Great Britain (15,000  volunteers, 27% 
of which were over 65), in a moment in which the UK 
variant was emerging and circulating widely. Sixty-
two COVID-19 cases were described in the trial, 6 of 
which were among the vaccinated subjects. Of these 
infections, half were caused by the UK variant, allowing 
to estimate an efficacy of the vaccine against the Wuhan 
strain of 95.6% and against the British variant B.1.1.7 of 
85.6% [22]. A smaller phase 2b clinical trial conducted 
in South Africa (4,400  volunteers, 6% of which were 
HIV-positive) could raise doubts regarding its efficacy 
on variants. In that context, an antibody-resistant variant 
was found in a high percentage of infected persons 
(90%), lowering the overall efficacy of the vaccine to 
60% (95% CI: 19.9-80.1%) and to 49% (95% CI: 6.1-
72.8%) among HIV-positive volunteers. A phase 3 trial 
is currently being carried out in the United States and 
Mexico (30,000  volunteers) to evaluate the efficacy, 
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safety and immunogenicity of this vaccine in different 
populations [23]. The vaccine is under rolling review since 
February 3rd, 2021 [24] and the European Commission 
is currently negotiating a pre-purchase contract with the 
company. The rolling review is a regulatory tool that 
EMA uses to speed up the evaluation of a drug during 
emergencies, this involves the EMA’s human medicines 
committee (CHMP), which reviews data coming from 
ongoing studies as soon as they become available. 
Valneva
Another vaccine in advanced phase of development is that 
of Valneva, a French-Austrian company. This vaccine uses 
inactivated viruses incapable of infecting and multiplying. 
The virus, despite being killed, maintains all its antigenic 
properties beyond the Spike protein. This characteristic 
makes it potentially more immunogenic. Valneva started 
its phase 1 and 2  trials in December 2020 on patients 
between 18 and 55 years of age [25].
Once studies are completed, both the Novavax and 
the Valneva vaccine manufacturers are likely to sign 
agreements with the EU for the provision of large 
quantities of vaccines. The negotiations between the 
EU and Valneva are on an advanced stage for a supply 
of up to 60 million doses of VLA2001  [26]. The EU 
is also close to reach a final agreement with Novavax 
for 100  million doses together with another optional 
100 million doses [27]. 
ReiThera
The ReiThera vaccine, developed by the Italian 
company from the Pomezia’s technopole together with 
the Spallanzani Hospital of Rome and the University 
of Padova, uses a technology that is very similar to that 
of AstraZeneca and that takes advantage of a primate’s 
adenovirus (from gorilla) modified so as to express 
the Spike protein. It recently obtained the green light 
by AIFA at the end of phase 1 showing safety and 
immunogenicity, and the testing is now proceeding with 
phase 2 of trial in different Italian centers [28]. Healthy 
adults will be included, followed by those over 65 and 
those affected by chronic conditions [29]. The objective 
is to rapidly obtain the required registration from both 
the Italian and EU medicine authorities and swiftly 
proceed with the large-scale utilization of the vaccine. 
The Italian Government is financing phase 2 and 3 of the 
trial which should be completed in June 2021. An effort 
was requested to the Italian Regional Governments to 
help finance an early production of the vaccine, trusting 
in the favorable outcome of the trial, in order to have 
the first doses readily available as soon as the vaccine is 
authorized thus shortening the time required to reach full 
production capacity.
CureVac
Early in February 2021, EMA started a rolling review 
of CureVac’s CVnCoV, a mRNA vaccine, based on 
preliminary results from laboratory and clinical studies 
[30]. The results of the rolling review will provide 
evidence for a possible marketing authorization. Phase 
1 study results showed a good tolerability together with 
a strong antibody and T cell response, reaching titers 
comparable to those of recovered COVID-19 patients. 
The vaccine should be administered twice, at day 1 and 
at day 29 and can be stored at suitable conditions (+5°C 
for at least three months and 24h at room temperature 
before administration)  [31]. Additionally, a preclinical 
study on mouse models showed protection against the 
“South African” SARS-CoV-2 variant. The HERALD 
study, a phase 2b/3 study initiated in December 2020 has 
so far recruited 40,000 participants worldwide and will 
further characterize the efficacy of the vaccine against 
SARS-CoV-2 and its variants [32]. 
Of interest, at the beginning of March 2021, the Swiss 
company signed an agreement with Novartis for the 
production of CVnCoV, which should start in the 2nd 
quarter of 2021, with the production of 50 million doses 
by the end of the year and further 200 million doses in 
2022 [32]. 
Sinovac 
At the beginning of May, EMA announced the starting 
of another rolling review, evaluating the efficacy and 
safety of the Chinese company Sinovac Life Sciences 
Co. (Life’On) vaccine, Vero Cell Inactivated  [33]. 
The vaccine was first authorized in China in February 
2021 and has since then been authorized by more 
than 30  countries in adults older than 18 years, with 
260 million doses which have been already distributed 
worldwide [34]. 
Vero Cell is an inactivated viral vaccine containing 
inactivated SARS-CoV-2 as antigen, together with 
an adjuvant. The vaccination schedule consists in two 
administrations, at 14-28 days distance, and the vaccine 
can be stored at 2-8°C. Phase 3 studies are taking place 
in different countries (China, Brazil, Indonesia, Turkey, 
Chile). As of end of May 2021, the most common adverse 
events which were described are pain at the injection 
site, headache, fever and myalgia. In China, where 
more than 35  million doses have been administered, 
49 serious adverse events were reported. These include 
demyelination, cerebral hemorrhage, Henoch-Schönlein 
purpura, anaphylaxis and laryngeal edema. Overall, the 
vaccine showed an efficacy of 67% (95% CI: 65-69%) in 
preventing the infection and of 85% (95% CI: 83-87%) 
in preventing hospital admissions [34].
Is there an ideal COVID-19 vaccine?
With several COVID-19 vaccines now available and in 
an advance phase of the development pipeline, country 
authorities would be tempted to try and rank them to 
make a rational decision on which would better fit the 
needs of a certain country and that therefore should be 
adopted. However, the reality is that one cannot rely 
on a single vaccine when dealing with a pandemic 
emergency: the urgent need of billions of doses clashes 
with the production capacity of the pharmaceutical 
industry. There is no alternative therefore to the adoption 
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of all authorized vaccines and their urgent delivery to 
people through well-thought strategic campaigns. The 
development and validation of those still in trial phase 
is essential, as this is one important way to reduce the 
circulation of the virus and the potential emergence 
of new variants. The situation is extremely delicate: 
for the first time in the history of vaccination, a global 
immunization programme has started at a time of 
intense pandemic activity characterized by high virus 
transmission. This is a very favorable situation for the 
virus, facilitating selection of variants potentially able 
to escape the vaccine-induced antibody response. There 
is therefore no ideal vaccine, but there are many good 
vaccines to be used immediately. In other words, we do 
not have the ‘luxury’ of selecting one ideal product since 
to vaccinate billions in a very short time requires urgent 
adoption of all vaccines that are authorized.
Current vaccination campaign in Italy 
The anti-COVID vaccination campaign in Italy began 
in late December 2020 and has been structured in 
4 phases by the government. The strategy has been 
subsequently updated in early February 2021 after the 
approval of the AstraZeneca vaccine, which was shown 
to be suitable for the target population of phase 3 (school 
and university staff; armed police forces; prisons; 
community places)  [35]. More than 84 million doses 
should be administered (2 doses per vaccinated person) 
to achieve the goal of vaccinating 80% (conventionally 
established to guarantee herd immunity) of the Italian 
population by September 2021  [36]. As of 31 May 
2021, 34,900,000  doses had been administered and 
12,000,000 people had been fully vaccinated (of those, 
630,000 were vaccinated with a monodose vaccine), 
representing 20.38% of the total population  [37]. The 
initial slow coverage has been attributed mainly to delays 
in supply and distribution of vaccines by pharmaceutical 
companies, compounded with poor planning and 
organization of vaccination services in some regions. 
However, at the current pace and with the current 
average rate of daily vaccinations, it would take almost 
4 additional months to cover 70% of the population. 
Therefore, the government’s target would be reached 
by end of September 2021 (with a delay of one month 
with respect to deadline of end of August 2021 set by the 
government)  [38]. This situation could be complicated 
by the consideration that 70% vaccination coverage may 
no longer be sufficient to interrupt virus transmission 
given the new and more transmissible variants already 
circulating and progressively replacing the original strain 
of SARS-CoV-2 against which vaccines were produced.
Limitations of current vaccines
While an unprecedented research effort has in one 
year resulted in the development of numerous vaccine 
candidates and the introduction of large-scale campaigns 
of a few of them, there are important and critical 
limitations that may prevent a successful containment 
effort of the COVID-19 pandemic: the emergence 
of variants and the uncertainties around the duration 
of protection. These factors add to the widespread 
adverse feelings in some segments of the population 
that oppose vaccination practices due to ignorance and 
misinformation.
The appearance of virus variants is an expected event and 
is part of nature’s variability. The identification of variants 
is possible by applying advanced gene sequencing 
techniques capable of detecting mutations in the viral 
genome. These mutations occur more frequently in RNA 
viruses, including the influenza Orthomyxoviruses, 
Hepatitis C virus and HIV, especially when they find 
a way to replicate and widely spread in the population. 
Neutralizing antibodies are usually induced by infection 
or vaccination, so that a strong neutralizing antibody 
response is built up to suppress virus replication. A 
weak response does little to suppress replication, but 
neutralizing antibodies that have intermediate potency 
are thought to cause the virus to evolve and create ways 
to escape the constraint on its ability to replicate.
Therefore, the occurrence of SARS-CoV-2 mutations 
capable of producing variants able to replace original 
wild strains if they become more transmissible, was 
predictable. Among the SARS-CoV-2 genes that most 
frequently mutate there is the one encoding for the 
Spike protein. This protein is a key to transmission 
as it is involved in binding with the ACE human cell 
receptors and is also the target of neutralizing antibodies 
produced as part of the natural response or the vaccine. 
Data published by WHO on over 10,000 SARS-CoV-2 
genomes from 68 countries sequenced to date indicate 
the appearance of almost 6,000  mutated strains. 
Not unexpectedly, only a few of those became well 
established in the population by showing a relevant 
epidemiological advantage. Hence, the denomination 
of “variant”  [39]. The “English”, “South African”, 
“Brazilian” and “Indian” variants are among them. It 
is known today that all four variants are characterized 
by a higher transmissibility and the vaccine seems to be 
protective against the English one, while there are less 
certainties for the South African, Brazilian and Indian 
ones. Table  II shows the significant variants identified 
so far.
The most recent identified variant, the Indian one, has 
13 mutations, including two notable ones in the Spike 
protein that the virus uses to bind and infect cells. 
One of the mutations, E484Q, is similar to that found 
in the variants identified in South Africa and Brazil 
(E484K). The other, known as L452R, may boost viral 
transmission. The two mutations are in important parts 
of the structure of the Spike protein that is linked to the 
interaction of the virus with the host.
Scientists are also looking into a third mutation, P681R, 
which might help the virus replicate more quickly [40].
In laboratory-based studies, the South African variant 
was found to be partially resistant to neutralizing 
antibodies induced by 2 doses of the Pfizer mRNA 
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vaccine, the Moderna mRNA vaccine, and the Novavax 
protein vaccine  [41,  42]. Moreover, single-dose Pfizer 
vaccine serum antibodies were shown to be completely 
ineffective in neutralizing this particular variant. At 
present, most scientists active in this area are reasonably 
optimistic that the efficacy of the mRNA vaccines will 


























Johnson & Johnson: 
85-100%
Novavax: 95%





P681H (may increase 
the production of Spike 
proteins)
N501H (not likely to 
be involved in vaccine 
resistance)
H69-V70 
Y144/45 (may help evade 
antibodies)
Variant reported 




























Not known, but 
mutation may be 





N501Y (similar to N501H 
mutation)
K417N 
E484K (may help evade 
antibodies)
Variant reported 






































by 14 countries 
B.1.429 reported 
by 15 countries
Not yet shown 
to be more 
infectious, 
neither to be 






















not be substantially compromised by the South African 
and Brazilian variants, but there is a clear need for a 
definitive, national testing program to determine the 
properties of virus variants. Neutralizing antibodies 
induced by the AstraZeneca adenovirus vaccine had 
very low activity against the South African variant and 
the vaccine was ineffective at protecting against this 
strain [43].
Two doses of the Pfizer, Moderna, and Novavax vaccines 
are widely thought to be required for maximal efficacy, 
given that neutralizing antibodies can be detected 
after the first vaccine dose, but their titers are strongly 
boosted by the second one. Accordingly, the vaccines are 
less effective during the interdose period than after the 
second dose administration. Increased efficacy is not the 
only advantage of administering the second dose. In fact, 
when people are infected after the first dose but before 
the second dose, the virus can replicate in the setting of 
a suboptimal level of neutralizing antibodies, a situation 
in which resistant variants may emerge [44].
Another issue with significant implications involves what 
happens when a mRNA vaccine is given to a person who 
has recovered from COVID-19. Recent studies seemed 
to demonstrate that a single mRNA vaccine dose rapidly 
boosts neutralizing antibody titers to very high levels. 
Moreover, antibody responses against South African 
and Brazilian variants seems to be reduced in patients 
who had been infected with the Wuhan strain or United 
Kingdom variant but a single dose of Pfizer/BioNTech 
vaccine seems to increase neutralizing activity against 
them [45].
Considering the number of people in the world who have 
had COVID-19 and the possibility to only administer 
one dose to those who recovered from COVID-19, there 
is a potential to save a huge number of vaccine doses. 
A related issue is that the mRNA vaccines appear to 
trigger stronger adverse effects (headaches and mild 
fever) in people who have previously been infected with 
COVID-19. One potential solution to the adverse effect 
problem might be the administration of the Novavax 
protein vaccine. This vaccine seems to boost antibody 
levels in previously infected patients, particularly in 
younger individuals and to elicit fewer adverse effects 
than the mRNA vaccines with a similar efficacy. 
However, data from carefully designed clinical trials 
are needed to address these issues and inform the best 
decisions [46]. 
In conclusion, the more the virus changes and additional 
variants emerge and spread in the population, the more 
it will be necessary to adapt the vaccine formulations to 
obtain adequate protection for the population. However, 
anti-SARS-CoV-2 vaccines are able to elicit SARS-
CoV-2-specific CD4+ and CD8+ T cell responses [47] 
which do not seem to be impaired in the response to the 
variants [48].
Therefore, a major concern is that of the durability 
and duration of current vaccines which on the basis of 
the various clinical trials has been estimated to be in 
the range of 10-12 months. Continuous monitoring of 
circulating viral strains is therefore essential to assess 
the impact of variants on the efficacy of vaccines, besides 
the performance of diagnostic tests. Only through quick 
adaptation of diagnostic methods and vaccine composition 
can one hope to keep the pace with the rapid evolving 
of SARS-CoV-2. Modern technology should be able to 
cope with this natural phenomenon [49]. Initiatives such 
as that recently proposed by the European Commission 
and consisting in a bio-defense preparedness plan 
against COVID-19 variants called “HERA Incubator”, 
are necessary. This emergency program will tackle 
the short to medium-term threat and simultaneously 
prepare for the future. It will serve as the vanguard 
for the European Health Emergency Preparedness and 
Response Authority (HERA). HERA would provide 
a structural system to enable the EU to anticipate and 
tackle better future pandemics. In particular, work with 
researchers, biotechnology companies, manufacturers 
and public authorities has been planned to rapidly detect 
and analyze new variants, provide incentives to develop 
new and adapted vaccines, speed up the approval process 
and ensure scaling up of manufacturing capacities [50].
What’s the future of COVID-19?
The current COVID-19 pandemic has undoubtedly 
raised awareness of the impact infectious diseases may 
have on health, economy and society as a whole. The 
valuable lessons to learn from this situation can be 
summed up in three words: speed, preparedness and 
public health response. First, speed  has characterized not 
only the spread of the pandemic but also the deployment 
of all the efforts to counter it as well expressed by 
the rapid development of several diagnostic tests and 
vaccines which were authorized for use in less than a 
year. Secondly, preparedness is the key when fighting 
epidemics. To successfully organize a response and 
control effort while the epidemic is ongoing is a difficult 
task. Health systems and services need to be in place 
before an epidemic outbreak occurs. Preparedness is 
an essential requirement of the International Health 
Regulations (IHR) and signatory countries should 
implement a proper monitoring system based on the State 
Party self-assessment annual reporting tool and on joint 
external evaluations as recommended by WHO [51, 52]. 
Thirdly, the considerable impact of COVID-19 on 
society and the economy has abruptly brought the 
concept of an adequate public health response to the top 
of priorities of the contemporary highly inter-connected 
world: surveillance of new infections, rapid detection 
of epidemics, and ability to interrupt the transmission 
chain of the virus through pharmaceutical and non-
pharmaceutical tools are crucial interventions to be 
implement at local, national and global level. 
Vaccines have an established role in preventing pandemics 
and in curbing the spread of a disease like COVID-19. 
However, ensuring worldwide access to COVID-19 
vaccines remains a major concern. Authorizing the use 
of a product in a country does not automatically translate 
into wide access to all and especially the poorest and 
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most marginalized [53]. The price needs to be affordable 
and effective health systems must be in place to guarantee 
access at-scale. Crucially important are negotiations 
with industry that are crucial to facilitate access for the 
poorest countries. An initiative named COVAX has been 
established through an agreement among the Coalition 
for Epidemic Preparedness Innovations (CEPI), the 
GAVI Vaccine Alliance and WHO, jointly with the 
delivery partner UNICEF, with the aim to “accelerate 
the development and manufacture of COVID-19 
vaccines, and guarantee fair and equitable access for 
every country in the world” [54]. However, it has been 
previously reported that entities representing only 16% 
of the worldwide population secured 70% of the doses 
of vaccines available [54]. More recently, at the end of 
May 2021, high- and upper-middle income countries 
that include 50% of the worldwide population had 
administered 85% of all vaccines available, while low-
income countries, mostly in Africa, could access less 
than 1% of vaccines available worldwide [55]. COVAX 
has tried to address the inequity by shipping 76 million 
vaccines to 126 participants [56], in what is considered 
“the largest vaccine roll-out in history” [57]. While this 
is progress, it is far from sufficient to address the needs 
of the poorest countries. In the month of January 2021, 
WHO issued a call open to anybody in any country, 
including public health and political authorities as well 
as pharmaceutical companies, to build a global sense of 
solidarity and ensure that as soon as possible vaccination 
for the highest-risk people, especially the elderly and 
health workers, becomes possible everywhere [58]. 
Lately, several activist organizations have voiced their 
frustrations about the lack of access to vaccines in the 
poorest countries and issued calls to stakeholders to 
urgently find a solution. MSF, for instance, has applauded 
“the US government’s bold decision to support the 
waiving of intellectual property on COVID-19 vaccines 
during this time of unprecedented global need”  [59]. 
Likewise, the International Federation of the Red Cross 
has requested an acceleration, under the World Trade 
Organization (WTO) umbrella, of negotiations related 
to intellectual property and other barriers to a rapid 
scaling up of vaccine production all over the world [60]. 
A political debate has thus ensued. Already in October 
2020,  India and South Africa proposed a temporary 
waiver of certain Trade-Related Intellectual Property 
Rights (TRIPS) Agreement provisions to the WTO. 
Recently, this call has been backed by most low and 
middle-income countries as well as by the WHO. Despite 
the call, high-income countries, including the UK and the 
European Union where many pharmaceutical companies 
are located, have blocked negotiations and progress of the 
initiative. The political debate has thus created a divide 
between those for whom access to COVID-19 vaccines 
is a needed humanitarian gesture towards the poorer and 
those who instead are concerned about the consequences 
for the pharmaceutical industry that, deprived of the 
patent benefits, may reduce future involvement in 
research and development and loose motivation to invest 
in innovations. The political discussion continued during 
the Global Health Summit held in Rome on 21 May 2021 
in the context of the G20 Italian Presidency. Leaders of 
the G20 and several international organizations issued 
a document called “Rome Declaration” where, besides 
strong support to the prevention and preparedness efforts 
to be undertaken by all countries, a statement was made 
to be “working consistently within the TRIPS agreement 
and the 2001 Doha Declaration on the TRIPS agreement 
and Public Health; and Promoting the use of tools 
such as voluntary licencing agreements of intellectual 
property, voluntary technology and know-how transfers, 
and patent pooling on mutually-agreed terms”  [61]. 
Hopefully, this development will be the basis for a 
definitive solution to the issue of access to COVID-19 
vaccines for all countries worldwide.
In conclusion, as the WHO declaration spells out, 
“distributing COVID-19 vaccines quickly and equitably 
is essential to end this pandemic, restart our economies 
and begin to tackle the other great challenges of our 
time, like food insecurity, inequality and the climate 
crisis” [62]. 
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